Around 2010, a French biotech approached European officials with a wild idea. There are these viruses called bacteriophages, the team explained, which invade bacteria, multiply, and cause the pathogens to explode. As more and more bugs were becoming resistant to antibiotics, the company wanted to use these viruses to combat unrelenting infections — and proposed souping up these helpful parasites with some genetic modification.

The officials were not impressed. “The feedback the company received from the authorities was that it would be extremely difficult to get approval,” explained Guy-Charles Fanneau de la Horie, CEO of Pherecydes Pharma, “the issue being the dissemination of GMOs into nature. This is very sensitive in Europe.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy